Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00673881 · ClinicalTrials.gov registry record · Phase 1

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

A Phase 1 study of Dyslipidemia, sponsored by Radiant Research.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT00673881: Completed Phase 1 study of Dyslipidemia, sponsored by Radiant Research.

NCT00673881 is a Phase 1 study of Dyslipidemia that has completed, run by Radiant Research. The registered enrollment target is 25 participants, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00673881, a Phase 1 study of Dyslipidemia, has completed, sponsored by Radiant Research.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein \[HDL\] cholesterol levels and elevated triglyceride \[TG\] concentrations). 2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL. 3. To obtain pilot data for power calculations for subsequent comparative study.

Primary Outcome

Mean change in calculated LDL, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,average Day 95)

Conditions Studied

Interventions

  • DRUG choline fenofibrate

Study Locations (1)

Illinois

  • Radiant Research, 515 N State St, #2700 - Chicago

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2008-03
Est. Completion 2009-05
Phase Phase 1
Radiant Research

3 total trials

What the finished NCT00673881 record still lists

NCT00673881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 1 intervention - of which choline fenofibrate is the first listed.

NCT00673881 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00673881 about?

NCT00673881 is a clinical study titled "ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study". The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein \[HDL\] cholesterol levels and elevated triglycer...

What is the current status of trial NCT00673881?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-03. Estimated completion is 2009-05.

What conditions does trial NCT00673881 study?

This clinical trial studies the following conditions: Dyslipidemia.

What interventions are being tested in trial NCT00673881?

The interventions under investigation include: choline fenofibrate (DRUG).

Who is sponsoring clinical trial NCT00673881?

This trial is sponsored by Radiant Research, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00673881 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dyslipidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00673881's enrollment target sits among peer trials

25 35th of 40 higher than 6 of 40 other Dyslipidemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dyslipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00673881, the US trial registry maintained by the National Library of Medicine. NCT00673881 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.